drugset
drugset / Trial / NCT05307978

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

NCT05307978 ↗

Phase 1 Completed 48 enrolled Alexion Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindBasic science

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses (SADs) of ALXN1910 subcutaneous (SC) and SAD of ALXN1910 intravenous (IV).

Timeline

Start
2022-04-12
Primary completion
2023-02-07
Completion
2023-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ALXN1910 Unknown 5 mg Subcutaneous
Subject ALXN1910 Unknown 15 mg Subcutaneous
Subject ALXN1910 Unknown 45 mg Subcutaneous
Subject ALXN1910 Unknown 135 mg Subcutaneous

Indications

No indication recorded.